Holen Sie sich die Stockscreener-App
0.9999
3.80%
0.0366
Vorhandelsmarkt:
1.05
0.0501
+5.01%
Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten
Jaguar Health Inc (JAGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jaguar Health Inc (JAGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jaguar Health, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) - ACCESS Newswire
TradingKey - TradingKey
Jaguar Health (NASDAQ: JAGX) puts major dilution and incentive plan votes to investors - Stock Titan
Jaguar Health Inc (JAGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jaguar Health (JAGX) Secures Compassionate Use for Crofelemer in EU - GuruFocus
Jaguar Reports Up to 48% Lower Weekly Support in One MVID Patient - Stock Titan
Jaguar Health (JAGX) Registration filing Summary - Quartr
Jaguar Health Company Profile & Introduction - Moomoo
JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
Form S-1 Jaguar Health Inc For: 16 July By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health (NASDAQ: JAGX) plans 5.5M-share resale registration - Stock Titan
Jaguar Health (NASDAQ: JAGX) details 40.8M-share, $40M equity line - Stock Titan
Jaguar Health | S-1: General form for registration of securities under the Securities Act of 1933 - Moomoo
Jaguar Health Napo And Alivus Enter New Manufacturing And Supply Agreement For CrofelemerSEC Filing - TradingView
Jaguar Health Extends Crofelemer Supply With Alivus Through 2029, Adds Minimum Purchase Commitments - TradingView
Jaguar Health (NASDAQ: JAGX) signs new crofelemer manufacturing pact - Stock Titan
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program - ACCESS Newswire
MSN Money - MSN
Jaguar Health (JAGX) Lytham Partners Fall 2025 Investor Conference Summary - Quartr
Jaguar Health (JAGX) Proxy filing Summary - Quartr
Price to book forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health - ACCESS Newswire
Jaguar Health stock and its path in specialty pharma. Investors weigh volatile moves - ad-hoc-news.de
Jaguar Health (JAGX) Slides 7.6% as Selling Pressure Tests Key Support ZoneCalendar Spread Trade - dars.gov.et
JAGXJaguar Health Inc Latest SEC Filings - Finviz
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th - ACCESS Newswire
Jaguar Health, Inc. Files 8-K Report on July 1, 2026 – Key Company Information & SEC Disclosure Details - Minichart
Jaguar Health Inc. Q1 2026 Earnings: EPS Falls Far Below Estimates, Stock Edges Higher Despite No Revenue - dars.gov.et
Enterprise value to revenue forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Completes Conversion of Series O Preferred - TipRanks
Jaguar Health (JAGX) completes Series O preferred stock conversion to common shares - Stock Titan
Jaguar Health Inc. (JAGX) Holds Steady at $2.96 as Stock Consolidates Near Key LevelsTriple EMA - dars.gov.et
Jaguar Health (JAGX) Showcases Crofelemer Data at ESPGHAN Conference - GuruFocus
Jaguar Health reports crofelemer data for rare pediatric diseases By Investing.com - Investing.com Nigeria
Jaguar Health reports crofelemer data for rare pediatric diseases - Investing.com
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) - ACCESS Newswire
Jaguar Health says crofelemer cut one child's support needs by 48% - Stock Titan
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders - ACCESS Newswire
Enterprise value to EBIT forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
JAGX Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Rallies Despite SurpriseShare Dilution Risk - dars.gov.et
Price to earnings forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Price to earnings forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Price to book forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Enterprise value to revenue forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Jaguar Health shares after reverse split, small-cap biotech stock in the OTC market spotlight - AD HOC NEWS
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - GlobeNewswire Inc.
Enterprise value to EBITDA forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Inc (JAGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to EBITDA forward of Jaguar Health, Inc. – GETTEX:1JA1 - TradingView
Jaguar Health (JAGX) Announces Conversion of Series O Convertibl - GuruFocus
Jaguar Health Converts Series O Preferred Stock; Advances Crofelemer Program for Rare Intestinal Failure Diseases - Minichart
Series O preferred conversion at Jaguar Health (NASDAQ: JAGX) - Stock Titan
Price to sales forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend - ACCESS Newswire
Jaguar Health's one-time stock dividend converts into 3.209 shares - Stock Titan
Enterprise value to EBIT forward of Jaguar Health, Inc. – GETTEX:1JA1 - TradingView
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):